stockrowMedpace Holdings, Inc.
MEDP Healthcare Diagnostics & Research
Medpace Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.5 billion, up 20.0% from fiscal 2024.
- Revenue
- +8.50%
- EPS
- +24.6%
- Free cash flow
- −16.6%
Quarter to September 2026, against a year earlier
Follow MEDP
Alert me
Medpace Holdings, Inc. (MEDP) Return on equity
Medpace Holdings, Inc.'s return on equity over the twelve months to 30 September 2026 was 117.9%, up 47.6 percentage points from fiscal 2025 (70.2%). Over the past ten years it has ranged from −2.13% (fiscal 2015) to 70.2% (fiscal 2025) — the current reading is the highest in ten years. That is above the Diagnostics & Research industry median of 0.00% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 70.2% | 11.81 |
| FY2024 | 58.4% | (1.41) |
| FY2023 | 59.8% | 23.19 |
| FY2022 | 36.6% | 15.96 |
| FY2021 | 20.7% | 1.76 |
| FY2020 | 18.9% | 3.70 |
| FY2019 | 15.2% | 1.88 |
| FY2018 | 13.3% | 6.32 |
| FY2017 | 7.02% | 4.40 |
| FY2016 | 2.62% | 4.75 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| GH Guardant Health, Inc. compare | 153.9% |
| MEDP Medpace Holdings, Inc. | 117.9% |
| ILMN Illumina, Inc. compare | 32.4% |
| DGX Quest Diagnostics Incorporated compare | 14.8% |
| QGEN QIAGEN N.V. compare | 11.9% |
| LH Labcorp Holdings Inc. compare | 11.5% |
| ICLR ICON PLC compare | 4.86% |
| CRL Charles River Laboratories International, Inc. compare | 1.21% |
| RVTY Revvity Inc. compare | 0.00% |
| Diagnostics & Research industry median | 0.00% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on MEDP
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement